z-logo
Premium
Malignant transformation of a putative eyelid papilloma to squamous cell carcinoma in a dog
Author(s) -
Wiggans K. Tomo,
Hoover Clare E.,
Ehrhart E. J.,
Wobeser Bruce K.,
Cohen Loren B.,
Gionfriddo Juliet R.
Publication year - 2013
Publication title -
veterinary ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.594
H-Index - 50
eISSN - 1463-5224
pISSN - 1463-5216
DOI - 10.1111/j.1463-5224.2012.01062.x
Subject(s) - histopathology , eyelid , pathology , malignancy , medicine , malignant transformation , basal cell carcinoma , papilloma , biopsy , basal cell , ophthalmology
A 6‐year‐old female spayed Chihuahua was presented for the evaluation of generalized pigmented cutaneous masses, one of which was present on the lower right eyelid. The dog was not on immunosuppressive medications and did not have historical or laboratory evidence of underlying endocrine disease, including hypothyroidism and hyperadrenocorticism. Histopathology, immunohistochemistry, and polymerase chain reaction of a cutaneous biopsy from the left antebrachium containing representative lesions confirmed viral papillomatosis. Additionally, histopathology of the antebrachial mass revealed regions of epithelial dysplasia suggestive of possible early transformation to malignancy. Over the course of 5 months, the mass on the right lower eyelid progressed to encompass and efface the majority of the eyelid margin. Additionally, the eyelid tumor had changed from an ovoid, brown pigmented mass to an irregular, flesh‐colored mass. At the dog’s last recheck examination, a corneal ulcer had developed beneath the irregular dorsal margin of the tumor. Histopathology of the eyelid mass was consistent with squamous cell carcinoma (SCC) and was positive for the presence of papillomavirus using polymerase chain reaction. This report describes the transformation of a putative viral eyelid papilloma into a malignant SCC in an adult dog.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here